Science and Technology - Health / Medical Biology - Internal (Mains: General Studies-III) | Primary study: Communications Health, online 17 October 2026 | Published: 24 October 2026

Why in the News

Fatty liver, the accumulation of fat in the liver, is a major cause of chronic liver disease worldwide. Liver biopsy remains a reliable way to identify and grade it, but is invasive and unsuitable for screening millions of people. Indian researchers have identified plasma lipid signatures that helped distinguish healthy people, early fatty liver without steatohepatitis (No-MASH), and the more severe inflammatory form, MASH.

The exploratory cross-sectional study, by researchers from Amity University Haryana, IIT Delhi, AIIMS New Delhi, the Regional Centre for Biotechnology in Faridabad and Ashoka University, appeared open access in Communications Health on 17 October 2026. Samples were collected during 2021-2024; sample collection and publication are different dates.

Public-health scale: In February 2026, WHO's Executive Board described steatotic liver disease as a "missing link" in the global response to non-communicable diseases. It affects about 1.7 billion people and is increasing with obesity and diabetes, making affordable non-invasive tests a policy concern.

Examination perspective: Lipidomics, the broad study of bodily lipids, machine-learning diagnosis and biomarkers are relevant to GS-III science, technology and health. The study also raises why separate data are needed for Indian body profiles, including central fat and greater insulin resistance despite a lean appearance.

Institutional cooperation: Private universities, IIT, AIIMS, a government biotechnology centre and the instrument industry, SCIEX, collaborated. This illustrates the organisation of Indian research seeking to move laboratory findings towards medical use.

Background: From Fatty Liver to MASLD, and the Biopsy Barrier

Previously termed non-alcoholic fatty liver disease (NAFLD), the condition was renamed metabolic dysfunction-associated steatotic liver disease (MASLD) following international consensus in 2023. It concerns metabolically associated liver fat accumulation not caused by alcohol. The US National Institutes of Health describes a milder form with little or no inflammation or injury, and MASH, involving inflammation and cell damage with greater risks of fibrosis, cirrhosis and even liver cancer. Fibrosis is fibrous-tissue accumulation; cirrhosis is extensive permanent liver damage. Symptoms often appear late.

The journal page places global MASLD prevalence at about 32 per cent. The paper cites a regional range of 9-53 per cent among Indian adults, higher with metabolic syndrome. Diagnosis is difficult: biopsy is the gold standard but invasive, samples approximately 0.002 per cent of the liver, and is subject to variation between pathologists. Existing non-invasive tests have inconsistent accuracy.

Method: 99 Samples, Targeted Lipidomics and Machine Learning

The team obtained 99 plasma samples collected in 2021-2024: 96 from AIIMS New Delhi and three from the National Liver Disease Biobank at ILBS. These comprised 21 healthy participants, 35 No-MASH cases and 43 MASH cases. Patient diagnoses were biopsy-confirmed. No-MASH means MASLD without steatohepatitis; steatohepatitis combines fat accumulation with inflammation and cell injury.

Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS), which separates molecules in a mixture and measures their identities and quantities, measured lipid classes including ceramides, sphingomyelins, cholesteryl esters, triacylglycerols and glycerophospholipids. Stratified random splitting produced a discovery group of 69 and an internal validation group of 30.

A random forest model, a machine-learning method using many decision trees, was trained on statistically selected lipid signatures. SHAP analysis assessed each lipid's contribution to model decisions. For comparison, the team used Vanderbilt University's open US dataset, Metabolomics Workbench project PR000633. Their data were made available on Metabolomics Workbench as ST003816, with code on GitHub.

Findings: 16 Lipid Signatures, Three Distinct Comparisons

There were ten lipid signatures for healthy versus No-MASH participants, eight for healthy versus MASH, and two for No-MASH versus MASH: ceramide CER (20:1) and triacylglycerol TAG (52:4/FA18:1). Models jointly comparing healthy participants with the two patient groups achieved AUC 1.0, with a 95 per cent confidence interval (CI) of 1.00-1.00. For No-MASH versus MASH, AUC was 0.97 (95 per cent CI: 0.89-1.00), with 79.17 per cent accuracy.

The authors caution that these high AUC values describe mathematical separation in a small, selected sample, not certainty in a new population. Some No-MASH patients were classified as MASH in that comparison, but no MASH patient was misidentified. Overall, 16 lipid species were independent of covariates such as age, sex and BMI, the body-mass index calculated from weight and height.

Ten lipids, including CE (20:1), CER (22:0), HCER (d18:0/20:0), LCER (22:1) and PE (18:0/18:2), were elevated even in No-MASH. This suggests lipid disruption before severe inflammation and connects with known ceramide-inflammation-fibrosis biology. Agreement with Vanderbilt's external dataset was partial: some lipid changes were reproduced with statistical significance, others were not.

Limits and Cautions

  1. This cross-sectional study demonstrates associations, not causation or future progression.
  2. The sample was small, selected and biopsy-confirmed. High AUC and narrow confidence intervals reflect separation within this sample, not assured success in another population.
  3. Validation was internal. Similar performance on two computational platforms is not independent validation, and agreement with the external dataset was partial.
  4. The cohort was North Indian. The authors call for multicentre studies.
  5. The NAS tissue-based disease-activity classification has an ambiguous boundary: some No-MASH cases also had grade-1 inflammation.
  6. The 79.17 per cent No-MASH/MASH accuracy and overlapping risk scores show that separating adjacent stages remains difficult.
  7. LC-MS/MS is a specialist laboratory technique, not yet a routine blood test.
  8. This article relies directly on the primary paper; no independent news coverage was found.

Way Forward

  1. Independent multicentre validation: Test whether these signatures recur in larger, unselected groups from other regions, particularly India's diverse populations.
  2. Longitudinal testing: Examine whether the markers predict which No-MASH cases progress to MASH, rather than simply identify the current stage.
  3. Clinical use: Assess the distance from laboratory LC-MS/MS to affordable routine tests, including costs and a place in clinical guidelines.

Further global policy developments on steatotic liver disease following WHO's February 2026 proposal also deserve attention.

Sequence of Dates

Samples: 2021-2024. Research-code GitHub repository created: February 2025. Paper received: 18 December 2025; accepted: 31 August 2026; published online: 17 October 2026, according to both the journal and Crossref. WHO Executive Board resolution proposal: 3 February 2026. This article: 24 October 2026. Collection, publication, policy documents and news are distinct layers.

Reference Points for Readers

MASLD is metabolically associated fatty liver, previously called NAFLD. Distinguish No-MASH, without steatohepatitis, from MASH, with inflammation and cell injury. Sphingolipids such as ceramides support membranes and signalling; their accumulation has been associated with inflammation and fibrosis. Triacylglycerols are major energy-storage fats, while cholesteryl esters are a cholesterol transport form.

AUC is the area under the receiver operating characteristic (ROC) curve, a measure of a model's discriminatory ability. A value of 1.0 means perfect separation in the tested sample, not a guarantee for future populations, as the authors caution. Participating institutions included Amity University Haryana, including the first author; IIT Delhi; AIIMS New Delhi; RCB Faridabad; Ashoka University; and SCIEX Bengaluru.

Mains Practice Question

"Liver biopsy is unsuitable for population-scale screening; non-invasive biomarkers could fill this gap." Evaluate this statement using the recent Indian plasma-lipidomics study, and identify the main barriers to moving such markers from the laboratory into routine clinical practice. (General Studies-III: Science and Technology / Health; 250 words, 15 marks)

Sources and Limits

The primary paper and its full PDF provide the 99-sample design, methods, results, authors' limitations, discussion, internal validation and data availability. Crossref records online publication; WHO EB158.R1 provides the 3 February 2026 policy context; NIH explains MASLD and MASH. Dataset ST003816 is listed in the primary paper's data-availability statement.

Download This Article: PDF